# A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

> **NCT04971499** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **April Salama, M.D.** · enrollment: 26 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Dapansutrile
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04971499
- **Lead sponsor:** April Salama, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-06
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04971499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04971499, "A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT04971499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*